SecBot SecBot
SECBOTREPLAY Home › Report › PMVP

PMVP · Rezatapopt 48% ORR in ovarian

PMV Pharmaceuticals, Inc. · PRESS-RELEASE filed Nov 20, 2026 at 10:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Nov 20, 2026 at 10:30 ET

PMV Pharma reported positive Phase 2 data for rezatapopt in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer, with a 48% ORR and 10.4-month median duration of response in the primary analysis population. The company plans to submit an NDA for accelerated approval in Q1 2027.

  • 48% confirmed ORR in primary analysis of 65 platinum-resistant/refractory ovarian cancer patients
  • 10.4-month median duration of response in primary analysis population
  • 36% ORR across all 168 evaluable patients in overall population
  • NDA submission for accelerated approval planned in Q1 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access